Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.27
TFX's Cash to Debt is ranked higher than
52% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. TFX: 0.27 )
TFX' s 10-Year Cash to Debt Range
Min: 0.05   Max: 0.93
Current: 0.27

0.05
0.93
Equity to Asset 0.49
TFX's Equity to Asset is ranked higher than
58% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. TFX: 0.49 )
TFX' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.53
Current: 0.49

0.32
0.53
Interest Coverage 4.10
TFX's Interest Coverage is ranked lower than
55% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. TFX: 4.10 )
TFX' s 10-Year Interest Coverage Range
Min: 2.18   Max: 9.07
Current: 4.1

2.18
9.07
F-Score: 7
Z-Score: 2.19
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.87
TFX's Operating margin (%) is ranked higher than
88% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. TFX: 14.87 )
TFX' s 10-Year Operating margin (%) Range
Min: -6.28   Max: 16.28
Current: 14.87

-6.28
16.28
Net-margin (%) 9.47
TFX's Net-margin (%) is ranked higher than
84% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. TFX: 9.47 )
TFX' s 10-Year Net-margin (%) Range
Min: -12.25   Max: 21.66
Current: 9.47

-12.25
21.66
ROE (%) 8.88
TFX's ROE (%) is ranked higher than
80% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. TFX: 8.88 )
TFX' s 10-Year ROE (%) Range
Min: -10.11   Max: 21.44
Current: 8.88

-10.11
21.44
ROA (%) 4.22
TFX's ROA (%) is ranked higher than
77% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. TFX: 4.22 )
TFX' s 10-Year ROA (%) Range
Min: -4.96   Max: 8.55
Current: 4.22

-4.96
8.55
ROC (Joel Greenblatt) (%) 32.14
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. TFX: 32.14 )
TFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.47   Max: 34.38
Current: 32.14

-13.47
34.38
Revenue Growth (3Y)(%) 2.90
TFX's Revenue Growth (3Y)(%) is ranked higher than
71% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. TFX: 2.90 )
TFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -11   Max: 17.3
Current: 2.9

-11
17.3
EBITDA Growth (3Y)(%) 3.30
TFX's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. TFX: 3.30 )
TFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7.8   Max: 15.4
Current: 3.3

-7.8
15.4
EPS Growth (3Y)(%) 16.10
TFX's EPS Growth (3Y)(%) is ranked higher than
85% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. TFX: 16.10 )
TFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.4   Max: 16.4
Current: 16.1

-17.4
16.4
» TFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TFX Guru Trades in Q4 2013

Steven Cohen 13,271 sh (New)
Jim Simons 106,800 sh (New)
Murray Stahl 6,729 sh (+0.42%)
Chuck Royce 369,700 sh (unchged)
John Keeley 4,700 sh (unchged)
Manning & Napier Advisors, Inc 1,200,192 sh (-1.2%)
Robert Olstein 69,000 sh (-14.81%)
Third Avenue Management 369,692 sh (-33.72%)
» More
Q1 2014

TFX Guru Trades in Q1 2014

Paul Tudor Jones 2,900 sh (New)
Joel Greenblatt 11,603 sh (New)
Jim Simons 329,868 sh (+208.87%)
Third Avenue Management 369,692 sh (unchged)
Murray Stahl 6,679 sh (-0.74%)
Robert Olstein 65,000 sh (-5.8%)
Manning & Napier Advisors, Inc 1,038,814 sh (-13.45%)
Chuck Royce 309,700 sh (-16.23%)
John Keeley 3,820 sh (-18.72%)
Steven Cohen 4,300 sh (-67.6%)
» More
Q2 2014

TFX Guru Trades in Q2 2014

Joel Greenblatt 17,351 sh (+49.54%)
Jim Simons 375,400 sh (+13.8%)
Murray Stahl 6,679 sh (unchged)
John Keeley 3,820 sh (unchged)
Chuck Royce 309,700 sh (unchged)
Robert Olstein 63,000 sh (-3.08%)
Paul Tudor Jones 2,800 sh (-3.45%)
Third Avenue Management 270,465 sh (-26.84%)
Manning & Napier Advisors, Inc 2,190 sh (-99.79%)
» More
Q3 2014

TFX Guru Trades in Q3 2014

Joel Greenblatt 284,633 sh (+1540.44%)
Paul Tudor Jones 3,556 sh (+27%)
Manning & Napier Advisors, Inc 2,190 sh (unchged)
Chuck Royce 309,700 sh (unchged)
John Keeley 3,820 sh (unchged)
Robert Olstein 63,000 sh (unchged)
Jim Simons 360,000 sh (-4.1%)
Murray Stahl 6,384 sh (-4.42%)
Third Avenue Management 175,094 sh (-35.26%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 1540.44%0.28%$104.1 - $110.21 $ 117.5510%284633
Third Avenue Management 2014-09-30 Reduce -35.26%0.19%$104.1 - $110.21 $ 117.5510%175094
Third Avenue Management 2014-06-30 Reduce -26.84%0.21%$100.44 - $108.69 $ 117.5512%270465
Joel Greenblatt 2014-06-30 Add 49.54%0.01%$100.44 - $108.69 $ 117.5512%17351
Joel Greenblatt 2014-03-31 New Buy0.02%$90.94 - $106.1 $ 117.5520%11603
Third Avenue Management 2013-12-31 Reduce -33.72%0.3%$82.05 - $98.82 $ 117.5528%369692
Robert Olstein 2013-12-31 Reduce -14.81%0.15%$82.05 - $98.82 $ 117.5528%69000
Third Avenue Management 2013-09-30 Add 14.72%0.11%$75.01 - $82.07 $ 117.5550%557733
David Dreman 2013-09-30 Sold Out 0.09%$75.01 - $82.07 $ 117.5550%0
John Keeley 2013-09-30 Reduce -86.51%0.05%$75.01 - $82.07 $ 117.5550%4700
Third Avenue Management 2013-06-30 Reduce -36.69%0.44%$75.11 - $87.01 $ 117.5547%486168
Robert Olstein 2013-06-30 Reduce -20.21%0.28%$75.11 - $87.01 $ 117.5547%75000
David Dreman 2013-03-31 Reduce -90.77%0.84%$71.31 - $84.51 $ 117.5552%41925
Robert Olstein 2013-03-31 Reduce -24.8%0.45%$71.31 - $84.51 $ 117.5552%94000
John Keeley 2012-09-30 New Buy0.05%$60.55 - $70.62 $ 117.5583%33250
Third Avenue Management 2012-03-31 Add 28.54%0.27%$58.01 - $63.56 $ 117.55106%818706
Joel Greenblatt 2012-03-31 Sold Out 0.08%$58.01 - $63.56 $ 117.55106%0
Third Avenue Management 2011-09-30 Add 340.98%0.6%$49.51 - $63.14 $ 117.55107%572312
Joel Greenblatt 2011-09-30 Reduce -64.36%0.15%$49.51 - $63.14 $ 117.55107%9888
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.50
TFX's P/E(ttm) is ranked higher than
84% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 84.60 vs. TFX: 31.50 )
TFX' s 10-Year P/E(ttm) Range
Min: 4.99   Max: 258.41
Current: 31.5

4.99
258.41
P/B 2.57
TFX's P/B is ranked higher than
79% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. TFX: 2.57 )
TFX' s 10-Year P/B Range
Min: 1.04   Max: 2.61
Current: 2.57

1.04
2.61
P/S 2.98
TFX's P/S is ranked higher than
73% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. TFX: 2.98 )
TFX' s 10-Year P/S Range
Min: 0.71   Max: 3.02
Current: 2.98

0.71
3.02
PFCF 22.31
TFX's PFCF is ranked higher than
91% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 22.31 )
TFX' s 10-Year PFCF Range
Min: 5.92   Max: 51.16
Current: 22.31

5.92
51.16
EV-to-EBIT 20.94
TFX's EV-to-EBIT is ranked higher than
85% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. TFX: 20.94 )
TFX' s 10-Year EV-to-EBIT Range
Min: -39.5   Max: 23.7
Current: 20.94

-39.5
23.7
Shiller P/E 29.19
TFX's Shiller P/E is ranked higher than
91% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 29.19 )
TFX' s 10-Year Shiller P/E Range
Min: 10.28   Max: 29.57
Current: 29.19

10.28
29.57
Current Ratio 1.59
TFX's Current Ratio is ranked higher than
55% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. TFX: 1.59 )
TFX' s 10-Year Current Ratio Range
Min: 1.46   Max: 5.2
Current: 1.59

1.46
5.2
Quick Ratio 1.07
TFX's Quick Ratio is ranked higher than
54% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. TFX: 1.07 )
TFX' s 10-Year Quick Ratio Range
Min: 0.86   Max: 4.01
Current: 1.07

0.86
4.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.16
TFX's Dividend Yield is ranked lower than
55% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 1.35 vs. TFX: 1.16 )
TFX' s 10-Year Dividend Yield Range
Min: 1.14   Max: 3.48
Current: 1.16

1.14
3.48
Dividend Payout 0.36
TFX's Dividend Payout is ranked higher than
88% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 0.36 )
TFX' s 10-Year Dividend Payout Range
Min: 0.06   Max: 2.13
Current: 0.36

0.06
2.13
Yield on cost (5-Year) 1.20
TFX's Yield on cost (5-Year) is ranked lower than
55% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. TFX: 1.20 )
TFX' s 10-Year Yield on cost (5-Year) Range
Min: 1.14   Max: 3.48
Current: 1.2

1.14
3.48
Share Buyback Rate -2.70
TFX's Share Buyback Rate is ranked higher than
73% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. TFX: -2.70 )
TFX' s 10-Year Share Buyback Rate Range
Min: 1   Max: -2.7
Current: -2.7

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.80
TFX's Price/DCF (Projected) is ranked higher than
90% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 1.80 )
TFX' s 10-Year Price/DCF (Projected) Range
Min: 0.47   Max: 2.88
Current: 1.8

0.47
2.88
Price/Median PS Value 1.96
TFX's Price/Median PS Value is ranked higher than
58% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. TFX: 1.96 )
TFX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 1.82
Current: 1.96

0.48
1.82
Earnings Yield (Greenblatt) 4.80
TFX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. TFX: 4.80 )
TFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 10.8
Current: 4.8

4.2
10.8
Forward Rate of Return (Yacktman) 1.77
TFX's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.52 vs. TFX: 1.77 )
TFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 20.9
Current: 1.77

3.1
20.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TBH.Germany,
Teleflex Inc is a Delaware Corporation incorporated in 1943. The Company is a provider of medical technology products that provides clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 150 countries through a combination of its direct sales force and distributors. The Company manufactures its products at 27 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. It provides a broad-based platform of products, which it categorizes into four groups namely Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company's surgical products include ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company's surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company's diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP product lines feature the AutoCAT 2 WAVE console and the FiberOptix catheter, which together utilize fiber optic technology for arterial pressure signal acquisition and enable the patented WAVE timing algorithm to support the broadest range of patient heart rhythms, including severely arrhythmic patients. The Company's OEM division, which includes the TFX OEM(r) and Deknatel(r) OEM nameplates, provides custom-engineered extrusions, diagnostic and interventional catheters, sheath/dilator sets (introducers) and kits, sutures, perfo
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 
Teleflex Inc. Reports Operating Results (10-Q) Apr 28 2010 


More From Other Websites
Teleflex Partnership with ARCF Raises Funds for International Council for Respiratory Care at AARC... Dec 12 2014
Teleflex Partnership with ARCF Raises Funds for International Council for Respiratory Care at AARC... Dec 12 2014
Teleflex Partners with Premier to Expand Dialysis Portfolio Dec 03 2014
Teleflex Unites its World-Class Arrow®, Hudson RCI®, LMA® and Rusch® Brands at AARC 2014 Dec 03 2014
Teleflex Unites its World-Class Arrow®, Hudson RCI®, LMA® and Rusch® Brands at AARC 2014 Dec 03 2014
Teleflex Awarded Premier, Inc. Dialysis Agreement, Positioning Products for Future Growth Dec 02 2014
Teleflex Awarded Premier, Inc. Dialysis Agreement, Positioning Products for Future Growth Dec 02 2014
Teleflex to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 21 2014
Teleflex to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 18 2014
Teleflex (TFX) Hits 52-Week High on Strong Q3 Results Nov 17 2014
Teleflex Beats on Q3 Earnings & Revenues, Outlook Raised Nov 06 2014
TELEFLEX INC Financials Nov 05 2014
10-Q for Teleflex, Inc. Oct 31 2014
Teleflex to Introduce Innovative Portfolio at EMS World Expo 2014 Oct 30 2014
Teleflex to Introduce Innovative Portfolio at EMS World Expo 2014 Oct 30 2014
Teleflex beats Street 3Q forecasts Oct 29 2014
Teleflex beats Street 3Q forecasts Oct 29 2014
TELEFLEX INC Files SEC form 8-K, Regulation FD Disclosure Oct 29 2014
Teleflex Announces Quarterly Dividend Oct 29 2014
Teleflex Inc Earnings Call scheduled for 8:00 am ET today Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK